Product Overview
Description
CLPP-00150768 is recombinant human MYLIP protein
Protein Length
Full length protein
Nature
Recombinant Protein
Sequence
MHHHHHHDYKDDDDKLCYVTRPDAVLMEVEVEAKANGEDCLNQVCRRLGIIEVDYFGLQFTGSKGESLWLNLRNRISQQMDGLAPYRLKLRVKFFVEPHLILQEQTRHIFFLHIKEALLAGHLLCSPEQAVELSALLAQTKFGDYNQNTAKYNYEELCAKELSSATLNSIVAKHKELEGTSQASAEYQVLQIVSAMENYGIEWHSVRDSEGQKLLIGVGPEGISICKDDFSPINRIAYPVVQMATQSGKNVYLTVTKESGNSIVLLFKMISTRAASGLYRAITETHAFYRCDTVTSAVMMQYSRDLKGHLASLFLNENINLGKKYVFDIKRTSKEVYDHARRALYNAGVVDLVSRNNQSPSHSPLKSSESSMNCSSCEGLSCQQTRVLQEKLRKLKEAMLCMVCCEEEINSTFCPCGHTVCCESCAAQLQSCPVCRSRVEHVQHVYLPTHTSLLNLTVI
Sequence Similarities
Contains 1 FERM domain. Contains 1 RING-type zinc finger.
Predicted Molecular Weight
16 kDa including tags
Tags
His-DDDDK tag N-Terminus
Target Information
Alternative Names
BM-023; BZF1; E3 ubiquitin protein ligase MYLIP; E3 ubiquitin-protein ligase MYLIP; Idol; Inducible degrader of the LDL-receptor; Lipoprotein receptor; MIR; MYLIP; MYLIP_HUMAN; Myosin regulatory light chain interacting protein; PP5242
Protein Function
E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR.
Tissue Specificity
Ubiquitously expressed.
Shipping & Handling
Constituents
0.63% Tris HCl, 0.64% Sodium chloride, 0.017% Potassium chloride, 20% Glycerol (glycerin, glycerine)Contains 80 µg/ml DDDDK peptide.
Shipping
Shipped on Dry Ice.
